Potent Therapeutic Efficacy of a Novel HPV16E7-HBcAg-Hsp65 Fusion Protein Vaccine

Results: In TC-1 showed potent dose dependent therapeutic efficacy against and improved rates in the and high doses (30 μg). The three fusion components of VR 111 were all necessary to induce the best anti-tumor activity, CTL response and T cell proliferation. The tumor growth inhibition and a higher mouse survival rate were among the beneficial effects of cisplatin-based combination treatment. Moreover, the anti-tumor potency of VR 111 vaccine was proved to be significantly associated with E7 specific CD8 + T cell immune response and the adoptive lymphocyte transfer therapy also showed tumor growth inhibition. Conclusion: The results confirmed VR 111 as a potent therapeutic HPV vaccine candidate with superior anti-tumor efficacy in a murine model of HPV-induced cancer which its potentials could be considered for combination therapies against cervical cancer.